Success Metrics

Completion Rate
0%(0/1)
Active Trials
2(67%)
Terminated
1(33%)

Phase Distribution

Ph phase_3
1
33%
Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Active, not recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 31 (50.0%)
N/A1 (50.0%)

Trials by Status

active_not_recruiting267%
terminated133%

Recent Activity

2 active trials
Showing 3 of 3
active_not_recruitingphase_3

To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

NCT06901505
active_not_recruiting

A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept

NCT06971185
terminatednot_applicable

Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial

NCT03214627

Clinical Trials (3)

Showing 3 of 3 trials
NCT06901505Phase 3

To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

Active Not Recruiting
NCT06971185

A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept

Active Not Recruiting
NCT03214627Not Applicable

Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3